AERAS-404 + Placebo + Bacillus Calmette-Guérin (BCG)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Feb 1, 2014 → Oct 6, 2017
NCT ID
NCT02075203About AERAS-404 + Placebo + Bacillus Calmette-Guérin (BCG)
AERAS-404 + Placebo + Bacillus Calmette-Guérin (BCG) is a phase 2 stage product being developed by Sanofi for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02075203. Target conditions include Tuberculosis.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02075203 | Phase 2 | Completed |
Competing Products
20 competing products in Tuberculosis